Search research articles
Contact Us
Filters
Showing results (191-200 of 197) with videos related to
Page
of 20
Sort By:
You have reached the last page of results.
This site can display upto 197 results.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
|
April 14, 2024
Retrosigmoid versus middle fossa approach for hearing and facial nerve preservation in vestibular schwannoma surgery: A systematic review and comparative meta-analysis
Lucca B Palavani, Sávio Batista, Filipi Fim Andreão, et al.
Acta Crystallographica. Section D, Structural Biology
|
November 2, 2022
Glycoside hydrolase subfamily GH5_57 features a highly redesigned catalytic interface to process complex hetero-β-mannans
Marcele P Martins, Mariana A B Morais, Gabriela F Persinoti, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 31, 2003
Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial
Adriano Paccagnella, A Favaretto, F Oniga, et al.
BMJ Open
|
April 16, 2024
Study protocol: improving response to malaria in the Amazon through identification of inter-community networks and human mobility in border regions of Ecuador, Peru and Brazil
Mark M Janko, Andrea L Araujo, Edson J Ascencio, et al.
Medrxiv : the Preprint Server for Health Sciences
|
December 11, 2023
Network Profile: Improving Response to Malaria in the Amazon through Identification of Inter-Community Networks and Human Mobility in Border Regions of Ecuador, Peru, and Brazil
Mark M Janko, Andrea L Araujo, Edson J Ascencio, et al.
ESMO Open
|
June 19, 2021
Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078]
G L Banna, A Cortellini, D L Cortinovis, et al.
ESMO Open
|
March 18, 2021
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer
G L Banna, A Cortellini, D L Cortinovis, et al.
Page
of 20
Search research articles
Search
Showing results (191-200 of 197) with videos related to
Sort By:
Page
of 20
You have reached the last page of results.
This site can display upto 197 results.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
|
April 14, 2024
Retrosigmoid versus middle fossa approach for hearing and facial nerve preservation in vestibular schwannoma surgery: A systematic review and comparative meta-analysis
Lucca B Palavani, Sávio Batista, Filipi Fim Andreão, et al.
Acta Crystallographica. Section D, Structural Biology
|
November 2, 2022
Glycoside hydrolase subfamily GH5_57 features a highly redesigned catalytic interface to process complex hetero-β-mannans
Marcele P Martins, Mariana A B Morais, Gabriela F Persinoti, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 31, 2003
Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial
Adriano Paccagnella, A Favaretto, F Oniga, et al.
BMJ Open
|
April 16, 2024
Study protocol: improving response to malaria in the Amazon through identification of inter-community networks and human mobility in border regions of Ecuador, Peru and Brazil
Mark M Janko, Andrea L Araujo, Edson J Ascencio, et al.
Medrxiv : the Preprint Server for Health Sciences
|
December 11, 2023
Network Profile: Improving Response to Malaria in the Amazon through Identification of Inter-Community Networks and Human Mobility in Border Regions of Ecuador, Peru, and Brazil
Mark M Janko, Andrea L Araujo, Edson J Ascencio, et al.
ESMO Open
|
June 19, 2021
Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078]
G L Banna, A Cortellini, D L Cortinovis, et al.
ESMO Open
|
March 18, 2021
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer
G L Banna, A Cortellini, D L Cortinovis, et al.
Page
of 20